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Cerebral microbleeds (MBs) are potential risk factors for intracerebral haemorrhage (ICH) but it is unclear if 
they are a contraindication for antithrombotic drugs. Insights could be gained by pooling data on MB 
frequency stratified by antithrombotic-use in cohorts with ICH and ischaemic stroke (IS)/TIA. 
METHODS   
We performed a systematic review of published and unpublished data from cohorts with stroke or TIA to 
compare the presence of MBs in:  
1. Antithrombotic-users versus non-antithrombotic users with ICH  
2. Antithrombotic-users versus non-users with IS/TIA  
3. ICH versus ischaemic events stratified by antithrombotic-use  
We also analysed published and unpublished follow-up data to determine the risk of ICH in antithrombotic-
users with MBs. 
RESULTS  
In a pooled analysis of 1461 ICH and 3817 IS/TIA, MBs were more frequent in ICH versus IS/TIA in all 
treatment-groups, but the excess increased from 2.8 (2.3-3.5) in non-antithrombotic users to 5.7 (3.4-9.7) in 
antiplatelet-users and 8.0 (3.5-17.8) in warfarin-users (p-difference=0.01). There was also an excess of MBs in 
warfarin-users versus non-users with ICH (OR=2.7, 95%CI 1.6-4.4, p<0.001), but none in warfarin-users with 
IS/TIA (1.3, 0.9-1.7, p=0.33); p-difference=0.01. There was a smaller excess of MBs in antiplatelet-users 
versus non-users with ICH (1.7, 1.3-2.3, p<0.001), but findings were similar for antiplatelet-users with IS/TIA 
(1.4, 1.2-1.7, p<0.001); p-difference=0.25. In pooled follow-up data for 768 antithrombotic-users, presence of 




The excess of MBs in warfarin-users with ICH compared to other groups suggests that MBs increase the risk 
of warfarin-associated ICH. Limited prospective data corroborate these findings but larger prospective studies 
are urgently required. 
 
Introduction  
Increasing use of gradient-recalled echo (GRE) MRI has highlighted the association between 
cerebral microbleeds (MBs) and ischaemic stroke (IS) and TIA.1-6 MBs appear as small hypointense 
lesions on GRE-imaging,7 and correspond histologically to haemosiderin deposition in the peri-
vascular space in association with severe microangiopathy.8 MBs appear to predict future 
intracerebral haemorrhage (ICH) in prospective observational studies of patients with either 
ICH9,10or IS.2,11 This has led to concerns over the safety of antithrombotic drug use in patients with 
MBs, and some clinicians already regard MBs as a relative contraindication to warfarin-use.12 
However there is no clear evidence that MBs further increase the risk of antithrombotic-associated 
ICH. The number of outcomes in existing prospective studies has been small, and there has been 
insufficient power to stratify analyses by different drug treatments. Therefore there is a risk that 
clinicians are avoiding therapies of proven benefit unnecessarily. 
 
In the absence of large prospective studies, case-case comparisons of MB frequency between 
antithrombotic-users and non-users stratified by stroke type might provide useful insights. If MBs do 
increase the risk of antithrombotic-associated ICH, then we should find an increased frequency of 
MBs in cases with antithrombotic-associated ICH compared to “spontaneous” ICH. In case these 
comparisons are confounded by clinical differences between antithrombotic-users and non-users, 
comparisons of MB frequency in ICH versus ischaemic events within treatment groups are also 
needed, and these should show relatively more cases with MBs in association with ICH versus 
IS/TIA among antithrombotic-users compared to non-users.  We therefore aimed to study 
associations between antithrombotic-use and MBs by pooled case-case comparisons using data from 
both published and unpublished cohort studies with ICH and IS/TIA. We also looked at the 
 6
predictive power of MBs on baseline imaging after IS/TIA for risk of subsequent ICH in published 




We conducted a Medline search on 31st September 2009 using the terms “microbleed”, 
“microh(a)emorrhage”, “h(a)emorrhagic lacune”, and “stroke” or “TIA”, to identify cohort studies of 
patients with stroke and TIA who had undergone GRE-MRI to detect MBs. Further studies were 
identified by hand-searching the bibliographies of retrieved papers and reviews. We included studies 
of patients who had presented with an acute stroke or TIA, and that identified MBs in ≥10 subjects, 
and presented data on pre-morbid antithrombotic drug use according to the presence or absence of 
MBs, separating cases with IS/TIA and ICH, or these data were provided on application to the 
authors. We excluded studies of patients with vascular dementia, “chronic cerebrovascular disease,” 
or Binswanger’s disease. For each study we recorded inclusion and exclusion criteria, details of the 
imaging protocol, demographic data, prevalence of pre-morbid antithrombotic drug use, prevalence 
of previous stroke, and the proportion of patients with MBs. Where several papers had been 
produced from the same group, these were carefully reviewed to ensure that cohorts did not overlap.  
When it was not possible to determine this, data from the largest available cohort were taken.  
 
We also obtained previously unpublished data from 6 cohorts with recent stroke or TIA – the Oxford 
Regional Neurosciences Centres Cohort, the Prognosis of InTracerebral Cerebral Haemorrhage 
(PITCH) study, the Institute of Neurology Cohort, the Edinburgh Stroke Study, the Nishiogi-chuo 
Hospital Cohort, and the Suiseikai Kajikawa Hospital Cohort. Details of the methods of these studies 
including the imaging protocols are shown in table 1. Those cohorts that included patients with ICH 
excluded haemorrhages secondary to tumour, trauma, aneurysmal bleeds, cavernous malformation 
and vasculitis. Patients in each cohort were assessed by a neurologist, and demographic and clinical 
data including pre-morbid medication were recorded. Scans were reviewed by at least two observers 
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who were either neurologists or neuroradiologists and experienced in examining GRE-MRI. MBs 
were defined as hypointense lesions on GRE T2*-weighted MRI images measuring <10mm, with the 
exception of the Nishiogi-chuo Hospital Cohort, in which MBs measured 2-5mm. All images were 
assessed blind to clinical data. 
 
Finally we examined available prospective data on the risk of subsequent ICH in patients treated 
with antithrombotic medications who had undergone GRE-MRI following an index stroke or TIA.  
Prospective data were identified from the literature search and were available for 248 patients in the 
Oxford Neurosciences Centre Cohort who were also enrolled in the Oxford Vascular (OXVASC) 
study.13 OXVASC is a prospective population-based study of all vascular events, in which all 
patients are followed up at regular intervals after their index event. In addition all recurrent events in 
the population are identified through multiple overlapping methods of ascertainment. 
 
Statistical Analysis 
Using cross-sectional data from the above unpublished cohorts and all available published data from 
other cohort studies we calculated unadjusted odds ratios (OR) for finding MBs in:  
1. Antithrombotic-users versus non-users with ICH  
2. Antithrombotic-users versus non-users with ischaemic events  
3. ICH versus IS/TIA stratified by antithrombotic-use  
Using available prospective data we also calculated the OR for having a subsequent antithrombotic-
associated ICH in patients with MBs versus patients without MBs. 
 
If there were no patients with MBs in one of the above subgroups for any cohort study, we added 
0.05 to all 4 cells in the 2x2 table to enable graphic representation and CI estimation.14 ORs were 
then combined using the Mantel-Haenszel method. Heterogeneity between individual studies and 
between subgroups of studies was determined using the Chi-squared test. In-house software was used 
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for this meta-analysis. If a patient was taking a combination of antiplatelet agents and warfarin, they 





Results from the previously unpublished cohorts, including numbers of patients with ICH and 
ischaemic events, numbers of patients with MBs stratified by stroke type, and baseline demographic 
and risk factor data are presented in table 2. The frequency of MBs ranged from 11-38% in cohorts 
with IS/TIA, and from 37-64% in cohorts with ICH. The frequency of premorbid antiplatelet and 
warfarin-use also varied between studies, ranging from 4-42% and 0-23% respectively. 
 
The electronic search identified 174 articles. Of 70 potentially relevant cohort studies, 12 studies1, 5, 
15-24  including six cohorts with ICH and eight cohorts with ischaemic cerebrovascular events met our 
inclusion criteria. Details of these studies are shown in table 3. Patients were recruited and scanned 
within 24 hours of stroke onset in three studies,1,5,6 and <90 days in a further seven studies.15-19,21,24  
Three studies did not specify the delay between symptom onset and imaging.20,22,23 All studies used 
GRE-MRI to identify MBs, although magnet strength, imaging sequences, and slice thickness varied. 
The definition of MB size also varied: MBs measured ≤10mm in 4 studies,19,22-24 ≤7mm in 2 
studies,1,15 ≤5mm in 6 studies,6,16-18,20,21 and size was not defined in one study.5   
 
The pooled dataset included 1461 patients with ICH and 3817 patients with IS/TIA. Eight of the 
cohorts, contributing half the patients in this analysis were recruited from Asian populations, and the 
remaining studies were based in North American and European centres. The majority of data on 
patients with ICH came from Asian cohorts.  
 
 9
Results from the pooled analysis of published and unpublished data are shown in figure 1, stratified 
by event type. MBs were more frequent in warfarin-users with ICH compared to non antithrombotic-
users (OR 2.7, 95% CI 1.6-4.4, p<0.001), but were not more frequent in warfarin-users with IS/TIA 
(OR=1.3, 0.9-1.7, p=0.33); p-value of the difference between pooled ORs=0.01. In comparisons 
involving antiplatelet-users, the relationship between MB frequency and antiplatelet-associated ICH 
was similar but weaker. MBs were more frequent in antiplatelet-users versus non antithrombotic-
users with ICH (OR=1.7, 1.3-2.3, p<0.001), but the excess of MBs was not significantly different in 
the analysis of IS/TIA (OR=1.4, 1.2-1.7, p<0.001) - difference, p=0.25. Furthermore there was 
significant heterogeneity in the comparison involving antiplatelet-users with ICH, largely driven by a 
single out-lying cohort from Hiroshima. When data were re-analysed after removing this cohort, 
there was no longer a significant excess of MBs in antiplatelet-users versus non-users with ICH 
(OR=1.3, 0.9-1.8, p=0.10). 
 
Where cohorts included both ICH and ischaemic events, the frequencies of MBs in ICH versus 
ischaemic events were compared stratified by treatment group (figure 2). MBs were more frequent in 
ICH versus IS/TIA among all treatment groups, but this difference was greater among warfarin-users 
(OR=8.0, 95% CI 3.5-17.8) and antiplatelet-users (OR=5.7, 3.4-9.7) compared to non 
antithrombotic-users (OR=2.8, 2.3-3.5); p-value of the difference between pooled ORs=0.01. 
However once again, there was significant heterogeneity in the comparison involving antiplatelet-
users (p=0.02) largely driven by the cohort from Hiroshima, and when this was removed from the 
analysis the difference in MB frequency between antiplatelet-users with ICH and antiplatelet-users 
with ischaemic events fell (OR=2.6, 1.4-4.9), and was no different to the result seen in non 
antithrombotic-users; difference, p=0.83.   
 
Prospective data were available for 241 patients (135 males, mean age 67 years) with IS/TIA in the 
Oxford Neurosciences Centre cohort; 203 patients (34 with MBs) were started or continued on 
antiplatelet agents, and 16 patients (2 with MBs) were started or continued on warfarin after their 
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index event. The follow-up period was censored at 30/09/2009, providing a mean(SD) follow-up 
of 27(13) months. In this time 2 patients who both had MBs on their baseline scan had an ICH on 
follow-up; one was an antiplatelet-user and the other a warfarin-user. Published prospective data 
were also available from 3 other cohorts,2,11,25 details of which are included in table 3. The pooled 
prospective data-set included 768 patients with stroke or TIA (90 ICH, 123 TIA, 555 IS), with a 
mean follow-up period of 27.7 months. Of these, 482 were prescribed antiplatelet agents after their 
index event and 164 were prescribed warfarin. Among all antithrombotic-users the odds of a 
subsequent ICH in patients with MBs versus patients without MBs was 12.1 (95%CI 3.4-32.5), 
p<0.001 (fig 3) and among warfarin-users it was 3.0 (0.5-17.5), p=0.23, although this latter analysis 


























This is the first systematic evidence of an association between warfarin-associated ICH and MBs.  In 
a pooled analysis of 3817 patients with IS/TIA, and 1461 patients with ICH, we have shown an 
excess of MBs in warfarin-associated ICH, which was not found in warfarin-associated 
IS/TIA. Although there were relatively few data on warfarin-users, these preliminary results indicate 
that warfarin may be hazardous in patients with MBs. Similar but weaker associations between MB 
frequency and antiplatelet-associated ICH were also seen, but these results have to be interpreted 
with caution as there was significant heterogeneity between cohorts in analyses involving 
antiplatelet-associated ICH. The limited available prospective data also support the hypothesis that 
the presence of MBs increases the risk of future ICH as a complication of antithrombotic drug use. 
While we do not advise avoiding antithrombotic drugs in patients with MBs who have a high risk of 
future thromboembolic events, these data suggest that more prospective data on the safety of 
antithrombotic drugs in such patients are urgently required.  
 
There are a number of caveats regarding our interpretation of the cross-sectional data. Firstly 
comparisons in this study are not adjusted for all potential confounders. For example warfarin-users 
are more likely to have a history of hypertension or past stroke than non-users,26 and both risk factors 
are associated with an increased frequency of MBs.27 However we did not find an excess of MBs in 
warfarin-users versus non-users with IS/TIA, although similar differences in risk factors might be 
expected between these groups. In comparisons of MB frequency in ICH versus IS/TIA within 
treatment groups, cases were probably better matched. In this analysis we expected to find an excess 
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of MBs in cases with ICH versus cases with IS/TIA in all treatment groups,4,16,21 but the relative 
frequency of MBs in warfarin-associated ICH  was higher than the relative frequency in non 
antithrombotic-associated ICH. This again is consistent with the hypothesis that MBs are markers of 
increased bleeding risk on warfarin. Secondly, it is possible that warfarin causes MBs and this is the 
reason for the excess of MBs in warfarin-users with ICH. However if this were true, then we should 
have seen a similar excess of MBs in warfarin-users with IS/TIA as well.  
 
Our results are more difficult to interpret for antiplatelet-users. There was a weak association 
between MBs and antiplatelet-use among patients with ICH in particular, which was similar in 
magnitude to that reported recently in a cohort of predominantly healthy elderly individuals.28 
However this association was largely driven by the results of one large Japanese cohort, and 
disappeared when the results of this cohort were excluded from the analysis. Heterogeneity between 
cohorts of antiplatelet-users was perhaps not entirely unexpected as there may be groups of 
antiplatelet-users at higher risk of future ICH. There is evidence that the risk of future ICH increases 
with the number of MBs identified on a baseline scan.9,10 Moreover, lobar MBs may be a marker for 
cerebral amyloid angiopathy, an increasingly recognized cause of antithrombotic-related ICH; and it 
is therefore possible that multiple lobar MBs increase the risk of antiplatelet-related ICH. We were 
unable to stratify our findings by the number of antiplatelet agents used or the number and location 
of MBs present, but we are continuing to collect data to carry out these subgroup analyses.  
 
Prospective studies can provide more direct evidence about whether or not MBs increase the risk of 
antithrombotic-associated ICH, but so far have been limited by few warfarin-users, relatively short 
follow-up periods, and therefore insufficient numbers of outcome events to provide a reliable 
estimate of the risks of antithrombotic drug use in the presence of MBs.2,11,23,25 However, the limited 
prospective data that are available appear to show that MBs do increase the risk of ICH as a 
complication of antithrombotic-use. These results are also unadjusted for potential confounders, but 
are nevertheless consistent with the results of the pooled analysis of cross-sectional data, and 
 13
together make a compelling argument for the need for a collaborative prospective study of 
warfarin-users with microbleeds in particular.  
 
Our review presents data on MB frequency in the largest number of antithrombotic users with stroke 
to date, but does have some limitations. As has already been mentioned, there are still few data on 
the prevalence of MBs in warfarin-users with ICH, and although MBs are more frequent in these 
cases compared to other subgroups, the confidence limits for these estimates are wide. Secondly 
more data are required on ICH in non-Asian cohorts. The risk of antithrombotic-associated ICH 
appears to be highest in Asian patients,29 and so the apparent risk of antithrombotic-associated ICH 
in the presence of MBs may also differ between ethnic groups. Thirdly, our analysis might have 
underestimated the association between MBs and warfarin-associated ICH. Average haematoma 
volumes and case fatality rates are higher in warfarin-associated ICH compared to spontaneous 
ICH,26 potentially reducing MB detection rates in this group because patients are too clinically 
unstable to be scanned, and because MBs might be obscured by larger haematomas associated with 
increased oedema and distortion of brain parenchyma. Furthermore our analysis is not limited to 
cases with incident ICH.  Recurrent ICH is associated with a higher prevalence of MBs than incident 
ICH,3 and cases with recurrent ICH are less likely to be taking warfarin prior to their recurrent 
stroke.  
 
In some of the Oxford cohort, the imaging technique was not always optimal for highlighting MBs. 
Hybrid imaging techniques incorporating gradient and spin echos such as TGSE have the advantage 
of being fast and therefore useful in busy one-stop neurovascular clinics, but are less sensitive than 
gradient echo imaging for detecting MBs.30 Imaging sequences used by other studies in the 
systematic review also varied, and this might also have contributed to differences in the observed 
frequency of MBs.27,31  However, these issues are more relevant to inter-study comparisons, and 
should not have affected case-case comparisons between subgroups within each study.   
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ICH is the most feared complication of warfarin use, and is associated with very poor outcomes.26 
Warfarin-associated ICH makes up 14% of all ICH,32 and given the rising prevalence of atrial 
fibrillation and greater use of warfarin, its incidence is expected to rise.33 Therefore any means of 
better identifying patients at risk of warfarin-related complications is vital. Our study provides 
further evidence that MBs are likely to indicate an increased risk of ICH associated with warfarin-
use, and highlights the urgent need for more prospective studies of the safety of warfarin in patients 
with MBs. Data on the association between MBs and antiplatelet-associated ICH are less consistent, 




























Fig 1. Proportions of antithrombotic users versus non-antithrombotic users with at 
least one microbleed stratified by type of medication in cases with (A) intracerebral 
haemorrhage, and (B) ischaemic stroke and TIA 
 
Figure 2. Proportions of ICH events versus infarct/TIA events with visible MBs 
stratified by pre-morbid antithrombotic medication use. 
 
Fig 3 Frequency of ICH on follow-up in antithrombotic-users with MBs versus 
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Region Oxford, UK Lille, France London, UK Edinburgh, UK Tokyo, Japan Hiroshima, Japan 
Study period 9/2000 - 12/2008 11/2004- 12/2000 - 2/2008 4/2002 - 4/2005 1/2003 - 9/2005 4/2006 - 3/2009# 
Number  771 235 52 275 94 1396 
 
Event All stroke and TIA ICH, Warfarin 
users with IS 
ICH All stroke and 
TIA 
ICH All stroke 
Consecutive 
recruitment 
No Yes Yes No Yes Yes (from 10/2007) 
Magnet Strength (T) 1.5 1.5 1.5 1.5 1.0 1.5 












Slice thickness (mm) 5 5 5 5 6 5 
Gap thickness (mm) 1 1.5 1.5 1 1 1.5 
Median delay (IQR) to 
scan (days)  



























































 N=715 N=56 N=221 N=52 N=265 N=10 N=1064 N=332 N=94 
 (348 TIA/ 
367 stroke) 
   (10 TIA/ 
255 stroke) 
    
Mean Age (SD) years     70  (12)  74  (10)   67 (13.6)   67 (10.5)    70 (± 13) 70 (± 7)   72  (12)    68  (13)      65  (11) 
Males (%)   397  (56)  34  (61)  126  (57)   31  (60)    149  (56)   5  (50) 651  (61)  186  (56)      58  (62) 
Number with MBs (%)     80  (11)  20  (36)  119  (54)   30  (58)    100  (38)   6  (60) 379  (36)  200  (60)      60  (64) 
Risk factors          
  Hypertension (%)   404 (57)  40  (71)  140  (63)   44  (85)    138  (52)   4  (40) 708  (67)  296  (89)      93  (99) 
  Diabetes (%)     93  (13)    8  (14)    34  (15)     6  (12)      22  (8)   1  (10) 290  (27)    73  (22)      10  (11) 
  Hyperlipidemia (%)   285  (40)    6  (11)    68  (31)   22  (43)           -        - 400  (38)    92  (28)        1  (1) 
  Previous stroke (%)     69  (10)    8  (14)    28  (13)     6  (12)      35  (13)   2  (20) 338  (32)    97  (29)      18  (19) 
  Previous TIA (%)     30  (4)    5  (9)    14  (6)     6  (12)      47  (18)   2  (20)         -       -        - 
  IHD (%)   118  (17)    7  (13)    30  (14)     9  (17)      62  (23)   3  (30)         -       -        3  (3) 
  AF (%)     51  (7)  13  (23)    21  (10)     7  (13)      55  (21)   0  (0)         -       -        2  (2) 
Prior Antithrombotic use          
  Warfarin (%)     25  (4)    9  (16)    25  (11)     2  (4)      10  (4)   0  (0)  118  (11)    56  (17)        2  (2) 
  Antiplatelet (%)   238  (33)  16  (29)    62  (28)   17  (33)    112  (42)  30 (30)  279  (26)    15  (5)        9  (10) 
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107 ICH  62 59 70 24 3 25 1.5T  
284/20 
- - 
Copenhaver19  Washington 
USA 
87 ICH 68 46 57 59 9 14 1.5T   &   3.0T 
800/20      
















19 1.5 T 
500/14 
- - 
Soo23 Hong Kong 
China 










236 IS/TIA NR 55 19 24 NR 41 3T 
500/20 
- - 
Ovbiagele1 Los Angeles 
USA 





100 IS 60 58 20 27 NR 26 1.5T 
800/26 
- - 
Prospective studies           
Orken25 Istanbul 
Turkey 
141 IS 66 58 22 none 100 18 1.5T 
640/15 




  83 ICH 
67 63 35 66 none NR 1T 
4500/112 
18.6 10 
Fan2 Hong Kong 
China 
121 IS 68 68 36 80 6 41 1.5T 
300/30 
27.5 5 
Abbreviations: IS=ischaemic stroke, LI=Lacunar infarct, ICH=intracerebral haemorrhage,  NR = not reported       
